论文部分内容阅读
目的观察可切除的结直肠来源肝转移癌行肝部分切除术患者使用新辅助化疗后对肝功能的影响。方法对30例接受治疗的可切除的结直肠来源肝转移癌患者给予新辅助化疗,用药方案为mFOLFOX6(亚叶酸钙+奥沙利铂+5氟尿嘧啶)2~4疗程,所有患者均在停药1个月后接受肝部分切除术。观察这30例患者行肝部分切除术术前、术后1 d,1、2、6周时的AST、ALT、TBil、DBil水平变化。结果术后1 d以及1周时患者的AST、ALT、TBil、DBil水平均显著高于术前,差异有统计学意义(P<0.05),但第2周、第6周时患者的AST、ALT、TBil、DBil水平较术前差异无统计学意义(P>0.05)。结论结直肠来源肝转移癌行部分肝切除术的患者使用新辅助化疗肝功能在短时间内会有一定程度的不利影响,停药2个月后其影响会逐步消除。
Objective To investigate the effect of neoadjuvant chemotherapy on liver function in patients with resectable colorectal-derived liver metastases who underwent partial hepatectomy. Methods Neoadjuvant chemotherapy was given to 30 patients with resectable colorectal-derived liver metastases who received treatment. The medication regimen was 2 to 4 courses of mFOLFOX6 (leucovorin + oxaliplatin + 5 fluorouracil), and all patients were discontinued 1 month after partial hepatectomy. The changes of AST, ALT, TBil and DBil in these 30 patients before and 1, 2, and 6 weeks after hepatectomy were observed. Results The levels of AST, ALT, TBil and DBil in patients at 1 and 1 week after operation were significantly higher than those before operation (P <0.05). However, the levels of AST, The levels of ALT, TBil and DBil were not significantly different from those before operation (P> 0.05). Conclusions The patients with partial hepatectomy of colorectal liver metastasis who underwent neoadjuvant chemotherapy for liver function may have a certain degree of adverse effects in a short period of time. After 2 months of withdrawal, their effects will be gradually eliminated.